Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis
Not Applicable
- Conditions
- Acute ischemic stroke
- Registration Number
- JPRN-UMIN000022652
- Lead Sponsor
- Hyogo college of medicine
- Brief Summary
The cumulative incidence of primary outcome was similar between the two groups. The crude HR of the Early group was 1.19 and the adjusted HR was 1.32 within 365 days.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 713
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are considered to be ineligible for the study participation by the investigator. 2. Patients who are pregnant or potentially pregnant. 3. Patients who have a history of hypersensitivity to apixaban 4. Patients with hepatic disease having coagulation disorder and clinically important bleeding risk 5. Patients with renal failure (creatinine clearance<15 mL/min) 6. Patients with Active pathological bleeding including intracranial bleeding of any type
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Death and ischemic/bleeding events within 90 days after disease onset
- Secondary Outcome Measures
Name Time Method